Fragment-Based Drug Discovery

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 228-243

  Farmer, Bennett T ^a   Reitz, Allen B ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b Janssen Research and Development LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 74249105355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00011-1     Document Type: Chapter

References (67)

1. Jencks W.P. On the attribution and additivity of binding energies. Prod. Natl. Acad. Sci. USA 1981, 78:4046-4050.
2. Nakamura C.E., Abeles R.H. Mode of interaction of β-hydroxy-β-methylglutaryl coenzyme A reductase with strong binding inhibitors: compactin and related compounds. Biochemistry 1985, 24:1364-1376.
3. Hann M.M., Leach A.R., Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41:856-864.
4. Jahnke W., Flörsheimer A., Blommers M.J.J., Paris C.G., Heim J., Nalin C.M., Perez L.B. Second-site NMR screening and linker design. Curr. Top. Med. Chem. 2003, 3:69-80.
5. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6:211-219.
6. Bartoli S., Fincham C.I., Fattori D. The fragment-approach: an update. Drug Discov. Today: Technologies 2006, 3:425-431.
7. Zartler E.R., Shapiro M.J. Fragonomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 2005, 9:366-370.
8. Rees D.C., Cosgreve M., Murray C.W., Carr R. Fragment-based lead discovery. Nat. Rev. Drug. Discov. 2004, 3:660-672.
9. Erlanson D.A., McDowell R.S., O'Brien T. Fragment-based drug discovery. J. Med. Chem. 2007, 47:3463-3482.
10. Jahnke W., Erlanson D.A. Fragment-based approaches in drug discovery 2006, Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim, pp. 1-369.
11. Babaoglu K., Shoichet B.K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol. 2006, 2:720-723.
12. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
13. Nienaber V.L., Richardson P.L., Koighofer V., Bouska J.J., Giranda V.L., Greer J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 18:1105-1108.
14. Blaney J., Nienaber V., Burley S.K. Fragment-Based Approaches in Drug Discovery 2006, 215-248. Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim. W. Jahnke, D.A. Erlanson (Eds.).
15. Sen D.S. Fragment-Based Approaches in Drug Discovery 2006, 149-180. Wiley-VCH Verlag GmbH & Co. KgaA, Weinheim. W. Jahnke, D.A. Erlanson (Eds.).
16. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today. 2004, 9:430-431.
17. Davis A.M., Keeling D.J., Steele J., Tomkinson N.P., Tinker A.C. Components of successful lead generation. Curr. Top. Med. Chem. 2005, 5:421-439.
18. Michne W. Hit-to-lead chemistry: a key element in new lead generation. Pharmaceutical News 1996, 3:19-21.
19. Honma T. Recent advances in de novo design strategy for practical lead identification. Med. Res. Rev. 2003, 23:606-632.
20. Brown D., Superti-Furga G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 2003, 8:1067-1077.
21. Hird N. Isn't combinatorial chemistry just chemistry?. Drug Discov. Today 2000, 5:307-308.
22. Verdonk M.L., Hartshorn M.J. Structure-guided fragment screening for lead discovery. Curr. Opin. Drug Discov. Dev. 2004, 7:404-410.
23. Hajduk P.J., Sheppard G., Nettesheim D.G., Olejniczak E.T., Shuker S.B., Meadows R.P., Steinman D.H., Carrera G.M., Marcotte P.A., Severin J., Walter K., Smith H., Gubbins E., Simmer R., Holzman T.F., Morgan D.W., Davidsen S.K., Summers J.B., Fesik S.W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119:5818-5827.
24. Dickopf S., Frank M., Junker H.-D., Maier S., Metz G., Ottleben G., Rau H., Schellhaas N., Schmidt K., Sekul R., Vanier C., Vetter D., Czech J., Lorenz M., Matter H., Schudok M., Schreuder H., Will D.W., Nestler H.P. Custom chemical microarray production and affinity fingerprinting for the S1 pocket of factor VIIa. Anal. Biochem. 2004, 335:50-57.
25. Gill A., Cleasby A., Jhoti H. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput X-ray crystallography. Chem Bio Chem 2005, 6:506-512.
26. Schuffenhauer A., Ruedisser S., Marzinzik A.L., Jahnke W., Blommers M., Selzer P., Jacoby E. Library design for fragment-based screening. Curr. Top. Med. Chem. 2005, 5:751-762.
27. Oblak M., Grdadolnik S.G., Kotnik M., Jerala R., Filipic M., Solmajer T. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 2005, 15:5207-5210.
28. Roberts G.C.K. Applications of NMR in drug discovery. Drug Discov. Today 2000, 5:230-240.
29. Fejzo J., Lepre C., Xie X. Application of NMR screening in drug discovery. Curr. Top. Med. Chem. 2003, 3:81-97.
30. Gestwicki J.E., Hsieh H.V., Pitner J.B. Using receptor conformational change to detect low molecular weight analytes by surface plasmon resonance. Anal. Chem. 2001, 73:5732-5737.
31. Moy F.J., Haraki K., Mobilio D., Walker G., Powers R., Tabei K., Tong H., Siegel M.M. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Anal. Chem. 2001, 73:571-581.
32. Swayze E.E., Jefferson E.A., Sannes-Lowery K.A., Blyn L.B., Risen L.M., Arakawa S., Osgood S.S., Hofstadler S.A., Griffey R.H. SAR by MS: a ligand based technique for drug lead discovery against structured RNA targets. J. Med. Chem. 2002, 45:3816-3819.
33. Carr R., Congreve M., Murray C., Rees D. Fragment-based lead discovery: leads by design. Drug Discov. Today 2005, 10:987-992.
34. Boehm H.-J., Boehringer M., Bur D., Gmuender H., Huber W., Klaus W., Kostrewa D., Kuehne H., Luebbers T., Meunier-Keller N., Mueller F. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization, a promising alternative to random screening. J. Med. Chem. 2000, 43:2663-2674.
35. Schade M. NMR fragment screening: advantages and applications. IDrugs 2006, 9:110-113.
36. Cheng A.C., Coleman R.G., Smyth K.T., Cao Q., Soulard P., Caffrey D.R., Salzberg A.C., Huang E.S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 2007, 25:71-75.
37. Riley R. The potential pharmacological and toxicological impact of P450 screening. Curr. Opin. Drug Discov. Dev. 2001, 4:45-54.
38. Hajduk P.J. Fragment-based drug design: how big is too big?. J. Med. Chem. 2006, 49:6972-6976.
39. Siegel M.G., Vieth M. Drugs in other drugs: a new look at drugs as fragments. Drug Discov. Today 2007, 12:71-79.
40. Clark M., Guarnieri F., Shkurko I., Wiseman J. Grand canonical Monte Carlo simulation of ligand-protein binding. J. Chem. Inf. Mod. 2006, 46:231-242.
41. Moore W.R. Maximizing discovery efficiency with a computationally driven fragment approach. Curr. Opin. Drug Discov. Dev. 2005, 8:355-364.
42. Macura S., Ernst R.R. Elucidation of cross relaxation in liquids by two-dimensional NMR spectroscopy. Mol. Phys. 1980, 41:95-117.
43. Schurr J.M., Babcock H.P., Fujimoto B.S. A test of the model free formulas: effects of anisotropic rotational diffusion and dimerization. J. Magn. Reson. Ser. B 1994, 105:211-224.
44. Van Holde K.E. Physical biochemistry. Foundations of Modern Biochemistry Series 1971, Prentice-Hall, Inc., Englewood Cliffs, New Jersey.
45. Mayer M., Meyer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. 1999, 38:1784-1788.
46. Kalk A., Berendsen H.J.C. Proton magnetic relaxation and spin diffusion in proteins. J. Magn. Reson. 1976, 24:343-366.
47. 2 (CPMG) methods. J. Magn. Reson. Ser. B. 1994, 104:266-275.
48. Fielding L., Fletcher D., Rutherford S., Kaur J., Mestres J. Exploring the active site of human factor Xa protein by NMR screening of small molecule probes. Org. Biomol. Chem. 2003, 1:4235-4241.
49. Gabriel B., Stubbs M.T., Bergner A., Hauptmann J., Bode W., Stürzebecher J., Moroder L. Design of benzamidine-type inhibitors of factor Xa. J. Med. Chem. 1998, 41:4240-4250.
50. 13C chemical shifts. J. Mol. Biol. 1997, 267:933-952.
51. Rondeau J.-M., Schreuder H. Protein crystallography and drug discovery. The Practice of Medicinal Chemistry 2003, 417-444. Elsevier Academic Press, New York. 2nd Edition. C.A. Wermuth (Ed.).
52. Hartshorn M.J., Murray C.W., Cleasby A., Frederickson M., Tickle I.J., Jhoti H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48:403-413.
53. Gill A.L., Frederickson M., Cleasby A., Woodhead S.J., Carr M.G., Woodhead A.J., Walker M.T., Congreve M.S., Devine L.A., Tisi D., O'Reilly M., Seavers L.C.A., Davis D.J., Curry J., Anthony R., Padova A., Murray C.W., Carr R.A.E., Jhoti H. Identification of p38a kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48:414-426.
54. Card G.L., Blasdel L., England B.P., Zhang C., Suzuki Y., Gillette S., Fong D., Ibrahim P.N., Artis D.R., Bollag G., Milburn M.V., Kim S.-H., Schlessinger J., Zhang K.Y.L. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. 2005, 23:201-207.
55. Bosch J., Robien M.A., Mehlin C., Boni E., Riechers A., Buckner F.S., Van Voorhis W.C., Myler P.J., Worthey E.A., DeTitta G., Luft J.R., Lauricella A., Gulde S., Anderson L.A., Kalyuzhniy O., Neely H.M., Ross J., Earnest T.N., Soltis M., Schoenfeld L., Zucker F., Merritt E.A., Fan E., Verlinde C.L.M.J., Hol W.G.J. Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J. Med. Chem. 2006, 49:5939-5946.
56. Wood W.J.L., Patterson A.W., Tsuruoka H., Jain R.K., Ellman J.A. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc. 2005, 127:15521-15527.
57. Salisbury C.M., Ellman J.A. Rapid identification of potent nonpeptidic serine protease inhibitors. ChemBioChem 2006, 7:1034-1037.
58. Patterson A.W., Wood W.J.L., Hornsby M., Lesley S., Spraggon G., Ellman J.A. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J. Med. Chem. 2006, 49:6298-6307.
59. Erlanson D.A., Wells J.A., Braisted A.C. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 2004, 33:199-223.
60. Whiting M., Muldoon J., Lin Y.-C., Silverman S.M., Lindstrom W., Olson A.J., Kolb H.C., Finn M.G., Sharpless K.B., Elder J.H., Fokin V.V. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew. Chem. Int. Ed. 2006, 45:1435-1439.
61. Manetsch R., Krasinski A., Radic Z., Raushel J., Taylor P., Sharpless K.B., Kolb H.C. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 2004, 126:12809-12818.
62. Lewis W.G., Green L.G., Grynszpan F., Radic Z., Carlier P.R., Taylor P., Finn M.G., Sharpless K.B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. 2002, 41:1053-1057.
63. Mocharla V.P., Colasson B., Lee L.V., Roper S., Sharpless K.B., Wong C.-H., Kolb H.C. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Angew. Chem. Int. Ed. 2005, 44:116-120.
64. Neumann T., Junker H.-D., Keil O., Burkert K., Ottleben H., Gamer J., Sekul R., Deppe H., Feurer A., Tomandl D., Metz G. Discovery of thrombin inhibitor fragments from chemical microarray screening. Lett. Drug Design Discov. 2005, 2:590-594.
65. Ciulli A., Williams G., Smith A.G., Blundell T.L., Abell C. Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. J. Med. Chem. 2006, 49:4992-5000.
66. Hofstadler S.A., Sannes-Lowery K.A. Applications of ESI-MS in drug discovery: interrogation of noncovalent complexes. Nat. Rev. Drug Discov. 2006, 5:585-595.
67. Oslob J.D., Erlanson D.A. Tethering in early target assessment. Drug Discov. Today: Targets 2004, 3:143-150.